Santa Clara, Calif., April 5, 2016 — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.
“Up until now, the lack of models available to test the in vivo efficacy of new antibody-based immunotherapies and combination therapies has hindered the research process,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
Syngeneic mouse tumor models, commonly used for testing surrogate anti-mouse PD-1 antibodies, cannot serve as models for human-specific therapeutics. CrownBio’s HuGEMM™, which was developed by directly replacing the murine PD-1 protein with its human counterpart, can be used to evaluate human therapeutics for checkpoint inhibitors including but not limited to anti-human PD-1, anti-human PD-L1 and anti-human CTLA-4 antibodies.
With the inclusion of the HuGEMM™ models, CrownBio solidifies its role as a leader in the preclinical immuno-oncology space. HuGEMM™ joins a portfolio of well-established translational model platforms, including the collection of HuPrime® cancer models available through the company’s HuBase® annotated database.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...